Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.3.0.814
Segments
9 Months Ended
Sep. 30, 2015
Segment Reporting [Abstract]  
Segments

14.

Segments

We report information about our operating segments using the “management approach” in accordance with current accounting standards.  This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance.  Our reportable segments are identified based on differences in products, services and markets served.  There were no inter-segment sales.  Prior to 2015, our products and development programs were all related to diagnostic substances.  Our majority-owned subsidiary, Macrophage Therapeutics, Inc., was formed and received initial funding during the first quarter of 2015, which resulted in a re-evaluation of the Company's segment determination.  We now manage our business based on two primary types of drug products: (i) diagnostic substances, including Lymphoseek and other diagnostic applications of our Manocept platform, our R-NAV subsidiary, NAV4694 and NAV5001, and (ii) therapeutic development programs, including therapeutic applications of our Manocept platform and all development programs undertaken by Macrophage Therapeutics, Inc.

The information in the following tables is derived directly from each reportable segment’s financial reporting.

 

Three Months Ended September 30, 2015

 

Diagnostics

 

 

Therapeutics

 

 

Corporate

 

 

Total

 

Lymphoseek sales revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States1

 

$

2,942,498

 

 

$

 

 

$

 

 

$

2,942,498

 

International

 

 

10,024

 

 

 

 

 

 

 

 

 

10,024

 

Lymphoseek license revenue

 

 

550,000

 

 

 

 

 

 

 

 

 

550,000

 

Grant and other revenue

 

 

476,755

 

 

 

 

 

 

 

 

 

476,755

 

Total revenue

 

 

3,979,277

 

 

 

 

 

 

 

 

 

3,979,277

 

Cost of goods sold, excluding depreciation and amortization

 

 

442,094

 

 

 

 

 

 

 

 

 

442,094

 

Research and development expenses,

   excluding depreciation and amortization

 

 

3,603,501

 

 

 

297,137

 

 

 

 

 

 

3,900,638

 

Selling, general and administrative expenses,

   excluding depreciation and amortization2

 

 

1,063,062

 

 

 

42,487

 

 

 

2,721,844

 

 

 

3,827,393

 

Depreciation and amortization3

 

 

17,013

 

 

 

 

 

 

115,216

 

 

 

132,229

 

Loss from operations4

 

 

(1,146,393

)

 

 

(339,624

)

 

 

(2,837,060

)

 

 

(4,323,077

)

Other income (expense), excluding

   equity in the loss of R-NAV, LLC5

 

 

 

 

 

 

 

 

(3,721,242

)

 

 

(3,721,242

)

Equity in the loss of R-NAV, LLC

 

 

 

 

 

 

 

 

(26,785

)

 

 

(26,785

)

Net loss

 

 

(1,146,393

)

 

 

(339,624

)

 

 

(6,585,087

)

 

 

(8,071,104

)

Total assets, net of depreciation and amortization:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

 

3,750,702

 

 

 

 

 

 

13,291,939

 

 

 

17,042,641

 

International

 

 

440,349

 

 

 

 

 

 

467

 

 

 

440,816

 

Capital expenditures

 

 

 

 

 

 

 

 

2,788

 

 

 

2,788

 

 

Nine Months Ended September 30, 2015

 

Diagnostics

 

 

Therapeutics

 

 

Corporate

 

 

Total

 

Lymphoseek sales revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States1

 

$

6,736,418

 

 

$

 

 

$

 

 

$

6,736,418

 

International

 

 

15,074

 

 

 

 

 

 

 

 

 

15,074

 

Lymphoseek license revenue

 

 

883,333

 

 

 

 

 

 

 

 

 

883,333

 

Grant and other revenue

 

 

1,320,816

 

 

 

 

 

 

 

 

 

1,320,816

 

Total revenue

 

 

8,955,641

 

 

 

 

 

 

 

 

 

8,955,641

 

Cost of goods sold, excluding depreciation and amortization

 

 

1,167,141

 

 

 

 

 

 

 

 

 

1,167,141

 

Research and development expenses,

   excluding depreciation and amortization

 

 

9,610,012

 

 

 

559,888

 

 

 

 

 

 

10,169,900

 

Selling, general and administrative expenses,

   excluding depreciation and amortization2

 

 

4,634,279

 

 

 

120,872

 

 

 

8,381,910

 

 

 

13,137,061

 

Depreciation and amortization3

 

 

207,498

 

 

 

 

 

 

223,870

 

 

 

431,368

 

Loss from operations4

 

 

(6,663,289

)

 

 

(680,760

)

 

 

(8,605,780

)

 

 

(15,949,829

)

Other income (expense), excluding

   equity in the loss of R-NAV, LLC5

 

 

 

 

 

 

 

 

(8,808,202

)

 

 

(8,808,202

)

Equity in the loss of R-NAV, LLC

 

 

 

 

 

 

 

 

(295,217

)

 

 

(295,217

)

Net loss

 

 

(6,663,289

)

 

 

(680,760

)

 

 

(17,709,199

)

 

 

(25,053,248

)

Total assets, net of depreciation and amortization:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

 

3,750,702

 

 

 

 

 

 

13,291,939

 

 

 

17,042,641

 

International

 

 

440,349

 

 

 

 

 

 

467

 

 

 

440,816

 

Capital expenditures

 

 

25,492

 

 

 

 

 

 

4,914

 

 

 

30,406

 

 

 

1

All sales to Cardinal Health are made in the United States; Cardinal distributes the product throughout the U.S. through its network of nuclear pharmacies.

 

2

General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments.  Marketing and selling expenses are allocated to our individual reportable segments.

 

3

Depreciation and amortization is reflected in cost of goods sold ($15,496 and $72,237 for the three and nine months ended September 30, 2015), research and development ($1,517 and $10,617 for the three and nine months ended September 30, 2015), and selling, general and administrative expenses ($115,216 and $348,514 for the three and nine months ended September 30, 2015).

 

4

Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.

 

5

Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.